Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Macrogenics Licenses Antibody Technology

by Ann M. Thayer
November 1, 2010 | A version of this story appeared in Volume 88, Issue 44

MacroGenics has signed two deals to develop drugs using its Dual-Affinity Re-Targeting antibody technology. With Boehringer Ingelheim, it will apply DART against up to 10 combinations of molecular targets in several disease areas. MacroGenics will receive $60 million in fees and R&D funding over three years and possibly $210 million in milestones for each of the 10 programs. Boehringer expects to make an equity investment in the company as well. MacroGenics also will work with Pfizer on two cancer targets for an undisclosed amount of R&D funding and milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.